This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Oncology  • Lung Cancer  • Pulmonary Diseases  • Pulmonary Diseases, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: In response to Drs Ardizzoni and Tiseo, we documented disease progression or treatment intolerability as the reason for discontinuation of prior therapy in all patients. However, we did not measure best overall response to chemotherapy given prior to enrollment. Therefore, we do not know if response to prior chemotherapy predicts sensitivity to gefitinib. However, we recorded the time from cancer diagnosis to the start of gefitinib therapy. For the 194 patients with no radiographic response, the median time from diagnosis to starting gefitinib was 19.8 months compared with 18.6 months for the 22 patients who had a radiographic response while receiving gefitinib. These data suggest that at least in terms of time from diagnosis, the natural history of non–small cell lung cancer in gefitinib-sensitive and gefitinib-resistant patients was comparable in our study.

We share the desire of Ardizzoni and Tiseo to identify patients with a higher probability of . . . [Full Text of this Article]

Mark G. Kris, MD
Department of Medicine
Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University
New York, NY

Andrea C. Kay, MD; Judith J. Ochs, MD; Michael K. Wolf, PhD
AstraZeneca Pharmaceuticals
Wilmington, Del

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Predictors of Clinical Response of Non–Small Cell Cancer to Gefitinib
Andrea Ardizzoni and Marcello Tiseo
JAMA. 2004;291(13):1563.
EXTRACT | FULL TEXT  

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Mark G. Kris, Ronald B. Natale, Roy S. Herbst, Thomas J. Lynch, Jr, Diane Prager, Chandra P. Belani, Joan H. Schiller, Karen Kelly, Harris Spiridonidis, Alan Sandler, Kathy S. Albain, David Cella, Michael K. Wolf, Steven D. Averbuch, Judith J. Ochs, and Andrea C. Kay
JAMA. 2003;290(16):2149-2158.
ABSTRACT | FULL TEXT